Biomarkers of Alzheimer disease in plasma

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

2002 • 6,780 citations

Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease

1993 • 3,693 citations

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

1995 • 3,645 citations

Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease

2002 • 3,174 citations

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1999 • 3,112 citations

Hearing loss and cognitive decline in older adults.

2013 • 2,798 citations

Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

1996 • 2,543 citations

A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease

1997 • 2,394 citations

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

2000 • 1,954 citations

The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease

1993 • 1,951 citations

Statins and the risk of dementia

2000 • 1,741 citations

Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study

2001 • 1,567 citations

Decreased Prevalence of Alzheimer Disease Associated With 3-Hydroxy-3-Methyglutaryl Coenzyme A Reductase Inhibitors

2000 • 1,415 citations

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial

2002 • 1,394 citations

Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study

1997 • 1,380 citations

Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

2003 • 1,373 citations

Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

2003 • 1,313 citations

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial

2002 • 1,028 citations

Cholesterol metabolism in the brain

2001 • 869 citations

Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease

2003 • 783 citations

Clinical biomarkers in drug discovery and development

2003 • 761 citations

A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes

1995 • 759 citations

Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients

1995 • 758 citations

Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death1

2002 • 700 citations

Serum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease

1998 • 669 citations

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”

1998 • 651 citations

Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain

1995 • 646 citations

Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease

2000 • 564 citations

Increase of Brain Oxidative Stress in Mild Cognitive Impairment

2002 • 563 citations

Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease

2002 • 557 citations

Use of Lipid-Lowering Agents, Indication Bias, and the Risk of Dementia in Community-Dwelling Elderly People

2002 • 519 citations

Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women

2002 • 432 citations

Plasma Aβ40 and Aβ42 and Alzheimer’s disease

2003 • 425 citations

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26‐week randomized, placebo‐controlled, double‐blind trial

2002 • 417 citations

Increased F₂‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidationin vivo

1998 • 411 citations

Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?

2000 • 384 citations

Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease

1996 • 384 citations

Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients

2000 • 374 citations

Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease

1995 • 372 citations

A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease

2003 • 365 citations

Increased 8,12-iso-iPF2?-VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity

2000 • 345 citations

Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia.

1999 • 328 citations

Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications

2002 • 323 citations

Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction.

1993 • 322 citations

Novel Therapeutic Approach for the Treatment of Alzheimer's Disease by Peripheral Administration of Agents with an Affinity to β-Amyloid

2003 • 322 citations

Standardization of measurement of β-amyloid_(1-42)in cerebrospinal fluid and plasma

2000 • 301 citations

Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease

2002 • 279 citations

Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease

2003 • 276 citations

Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels

2003 • 258 citations

Inflammation and therapeutic vaccination in CNS diseases

2002 • 254 citations

Plasma amyloid ?-peptide 1-42 and incipient Alzheimer's disease

1999 • 254 citations

Lipid Peroxidation and Free Radical Scavengers in Alzheimer’s Disease

1989 • 250 citations

Increased CSF F ₂ -isoprostane concentration in probable AD

1999 • 250 citations

Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde

2001 • 242 citations

Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms

1987 • 237 citations

Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease

1999 • 235 citations

Reduced levels of amyloid β-peptide antibody in Alzheimer disease

2001 • 231 citations

Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease

2001 • 226 citations

24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia

2002 • 224 citations

Fate of Cerebrospinal Fluid‐Borne Amyloid β‐Peptide: Rapid Clearance into Blood and Appreciable Accumulation by Cerebral Arteries

1996 • 223 citations

Homocysteine and Neurologic Disease

2000 • 213 citations

Serum cholesterol, APOE genotype, and the risk of Alzheimer’s disease: A population-based study of African Americans

2000 • 209 citations

Plasma Concentrations of Vitamins A and E and Carotenoids in Alzheimer's Disease

1992 • 201 citations

Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration

2003 • 183 citations

Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease

2009 • 175 citations

Mitochondrial involvement in Alzheimer’s disease

1999 • 169 citations

APOE genotype, plasma lipids, lipoproteins, and AD in community elderly

1999 • 169 citations

Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid

2002 • 168 citations

Reduction in Levels of 24S-Hydroxycholesterol by Statin Treatment in Patients With Alzheimer Disease

2003 • 165 citations

Circulating cytokines in Alzheimer's disease

1997 • 161 citations

Amyloid β protein in plasma from patients with sporadic Alzheimer's disease

1996 • 156 citations

Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls

2002 • 154 citations

Reduction of Plasma 24S-Hydroxycholesterol (Cerebrosterol) Levels Using High-Dosage Simvastatin in Patients With Hypercholesterolemia

2002 • 152 citations

Elevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome

2001 • 152 citations

Peripheral F₂‐isoprostanes and F₄‐neuroprostanes are not increased in Alzheimer's disease

2002 • 151 citations

Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group.

1998 • 149 citations

Blood Pressure, Cognitive Functions, and Prevention of Dementias in Older Patients With Hypertension

2001 • 146 citations

Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project

2000 • 143 citations

Autoantibodies to amyloid-? and Alzheimer's disease

2001 • 141 citations

Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers

2003 • 139 citations

Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease

2002 • 137 citations

Altered Amyloid Protein Processing in Platelets of Patients With Alzheimer Disease

1997 • 127 citations

Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease

1995 • 126 citations

Lipoprotein (a) and stroke

2000 • 122 citations

Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer’s disease

1999 • 114 citations

The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta 42(43)

1997 • 111 citations

Passage of human amyloid β-protein 1–40 across the murine blood-brain barrier

1994 • 109 citations

Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques.

1996 • 109 citations

Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases.

2000 • 106 citations

Platelet APP isoform ratios correlate with declining cognition in AD

2000 • 106 citations

Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease

1997 • 99 citations

Abnormalities in the Pattern of Platelet Amyloid Precursor Protein Forms in Patients With Mild Cognitive Impairment and Alzheimer Disease

2002 • 97 citations

Preferential deposition of amyloid β protein (Aβ) in the form Aβ40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele

1997 • 92 citations

Amyloid precursor protein in platelets

2001 • 90 citations

Combination of serum markers related to several mechanisms in Alzheimer’s disease

2003 • 87 citations

Serum cytokine levels in patients with Alzheimer's disease

1994 • 86 citations

Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease

1999 • 85 citations

Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease

1998 • 85 citations

Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease

2002 • 84 citations

Pharmacological concentrations of the HMG-COA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta -amyloid peptide em in vitro em and in patients

2002 • 83 citations

Serum Creatinine Levels Correlate With Plasma Amyloid β Protein

2002 • 82 citations

Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease

1990 • 79 citations

Amyloid Precursor Protein in Platelets of Patients With Alzheimer Disease

2001 • 78 citations

Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study

2000 • 75 citations

APOE ε3/ε4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer’s disease diagnosis

2003 • 65 citations

Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer’s disease (DAT): Lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT

1998 • 59 citations

Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study

1998 • 55 citations

Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer’s disease patients and centenarians

2003 • 49 citations

Pharmacological concentrations of the HMG-COA reductase inhibitor lovastatin decrease the formation of the Alzheimer b-amyloid peptide in vitro and in patients

2002 • 35 citations

Analysis of blood plasma proteins in patients with Alzheimer's disease by two-dimensional electrophoresis, sequence homology and immunodetection

2000 • 35 citations

Genotyping of Apolipoprotein <scp>E</scp>: Comparative Evaluation of Different Protocols

2003 • 32 citations

Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients

2003 • 31 citations

17beta-estradiol reduces plasma Abeta40 for HRT-naïve postmenopausal women with Alzheimer disease: a preliminary study.

2003 • 30 citations

Expression of apolipoprotein[a] and plasminogen mRNAs in cynomolgus monkey liver and extrahepatic tissues

1996 • 26 citations

High cholesterol affects platelet APP processing in controls and in AD patients

2003 • 25 citations

Lipoprotein(a) and Cognitive Performances in an Elderly White Population

2001 • 23 citations

530 Amyloid β protein (Aβ) deposition in normal aging has the same characteristics as that in Alzheimer's disease: Predominance of Aβ42(43) and association of Aβ40 with cored plaques and microglial cells

1996 • 18 citations

Deleted Work

1955 • 0 citations